amphetamine sulfate - Profile

What are the generic drug sources for amphetamine sulfate and what is the scope of patent protection?

Amphetamine sulfate is the generic ingredient in three branded drugs marketed by Azurity, Alkem Labs Ltd, Amneal Pharms, Aurolife Pharma Llc, Bionpharma, Dr Reddys Labs Sa, Epic Pharma Llc, Glenmark Pharms Ltd, Granules, Lannett, Novast Labs, Prinston Inc, Rhodes Pharms, Sanaluz, Senores Pharms, Specgx Llc, and Sun Pharm Inds Inc, and is included in eighteen NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Summary for amphetamine sulfate

US Patents:	3
Tradenames:	3
Applicants:	17
NDAs:	18

US Patents and Regulatory Information for amphetamine sulfate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Azurity	EVEKEO ODT	amphetamine sulfate	TABLET, ORALLY DISINTEGRATING;ORAL	209905-005	Apr 16, 2021		DISCN	Yes	No	10,441,554		Y
Azurity	EVEKEO ODT	amphetamine sulfate	TABLET, ORALLY DISINTEGRATING;ORAL	209905-005	Apr 16, 2021		DISCN	Yes	No	11,160,772		Y
Azurity	EVEKEO ODT	amphetamine sulfate	TABLET, ORALLY DISINTEGRATING;ORAL	209905-001	Jan 30, 2019		DISCN	Yes	No	11,896,562
Azurity	EVEKEO ODT	amphetamine sulfate	TABLET, ORALLY DISINTEGRATING;ORAL	209905-001	Jan 30, 2019		DISCN	Yes	No	10,441,554		Y
Azurity	EVEKEO ODT	amphetamine sulfate	TABLET, ORALLY DISINTEGRATING;ORAL	209905-001	Jan 30, 2019		DISCN	Yes	No	11,160,772		Y

Expired US Patents for amphetamine sulfate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Azurity	EVEKEO ODT	amphetamine sulfate	TABLET, ORALLY DISINTEGRATING;ORAL	209905-005	Apr 16, 2021	10,130,580
Azurity	EVEKEO ODT	amphetamine sulfate	TABLET, ORALLY DISINTEGRATING;ORAL	209905-002	Jan 30, 2019	10,130,580
Azurity	EVEKEO ODT	amphetamine sulfate	TABLET, ORALLY DISINTEGRATING;ORAL	209905-004	Jan 30, 2019	10,130,580
Azurity	EVEKEO ODT	amphetamine sulfate	TABLET, ORALLY DISINTEGRATING;ORAL	209905-003	Jan 30, 2019	10,130,580
Azurity	EVEKEO ODT	amphetamine sulfate	TABLET, ORALLY DISINTEGRATING;ORAL	209905-001	Jan 30, 2019	10,130,580

Investment Scenario and Fundamentals Analysis for Amphetamine Sulfate

Last updated: February 21, 2026

What is the Market Position of Amphetamine Sulfate?

Amphetamine sulfate is a central nervous system stimulant primarily used for treating Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy. It has a significant history of medical use, with a high likelihood of continued demand. The global market for prescription stimulants, including amphetamine-based medications, was valued at approximately $4 billion in 2022. Compound annual growth rate (CAGR) is projected at 3-5% through 2030, driven by increasing ADHD diagnosis rates and expanded mental health awareness.

How Are Regulatory and Patent Statuses Structured?

Regulatory Landscape

• FDA Approval: Amphetamine sulfate formulations are approved in the US, with some formulations dating back decades. Extended-release versions are under ongoing patent protections in certain regions.
• Global Availability: Permitted in Europe, Japan, and other major markets under strict scheduling (Schedule II in the US, Class B in the UK, etc.).

Patent and Exclusivity Status

• Patent Status: Original patents expired in the late 20th century. Current formulations are mostly off-patent, although specific extended-release versions may remain patented until 2024-2026.
• Market Exclusivity: Some companies hold data exclusivity or trademarks for branded formulations, offering limited barriers against generics.

What Are the Competitive Dynamics?

Key Competitors

• Generic Manufacturers: Rapidly increasing share post-patent expiry.
• Branded Variants: Maintained by a few firms with proprietary delivery mechanisms.
• Alternatives: Other stimulants (methylphenidate, dextroamphetamine) with similar therapeutic profiles.

Market Share Distribution (2022)

Segment	Market Share (%)	Key Players
Branded Drugs	25%	Shire, UCB, Lilly
Generics	60%	Teva, Sandoz, Mylan
New Formulations	15%	Otsuka, Allergan

What Are the Supply Chain and Manufacturing Considerations?

• Suppliers: Critical raw materials include ephedrine and phenylacetone, subject to regulation.
• Manufacturing: High compliance costs due to strict controls on production, handling, and distribution.
• Supply Risks: Potential shortages due to regulatory changes or geopolitical issues in key source countries.

How Do Legal and Policy Factors Affect Investment?

Abuse and Control Policies

• Strict scheduling in major markets to prevent misuse.
• Potential for regulations to tighten, impacting manufacturing licenses and distribution.

Legal Risks

• Increased regulatory oversight may lead to increased compliance costs.
• Risk of prescription restrictions or schedule reclassification, which could impair market access.

What is the Financial Outlook?

Revenue Drivers

• Growing demand for ADHD treatments.
• Launch of new formulations (extended-release or combination drugs).
• Expansion into emerging markets with rising mental health awareness.

Pricing Trends

• Prices fluctuate based on formulation type, regulatory environment, and competition.
• Branded drugs tend to command higher prices; generics bring price pressure.

Cost Factors

• High R&D and compliance costs reduce profit margins.
• Manufacturing costs are sensitive to raw material prices and regulatory compliance.

What Are the Key Risks?

• Regulatory changes limiting prescribing or distribution.
• Competition from generics reducing revenue.
• Supply chain disruptions impacting manufacturing.
• Litigation and legal challenges related to abuse potential.

Key Takeaways

• The market for amphetamine sulfate remains sizable, with steady growth driven by ADHD diagnosis rates.
• Revenue prospects decline with patent expiration, favoring generic manufacturers.
• Legal and regulatory frameworks impose operational costs and risks but serve to restrict unapproved use.
• Investment potential depends on the ability to develop or maintain formulations with proprietary features, regulatory positioning, and supply chain stability.

FAQs

1. How does patent expiration impact investment in amphetamine sulfate?
Patent expiration allows generics to enter the market, significantly reducing prices and profit margins for branded versions. Investment in proprietary formulations or delivery systems may mitigate this impact.

2. Are there risks of regulatory changes that could restrict amphetamine use?
Yes. Governments can tighten controls, reclassify formulations, or restrict prescribing, impacting revenue streams.

3. What are the main competitors in this market?
Generic manufacturers hold dominant market share; specialized branded formulations with novel delivery systems are niche competitors.

4. How do supply chain issues influence the market?
Dependence on regulated raw materials introduces risks of shortages, affecting manufacturing capacity and sales.

5. What is the growth outlook for amphetamine sulfate-based drugs?
While growth slows post-patent expiry, expanding diagnoses and new formulations support modest but steady demand growth.

---

References

1. MarketWatch. (2023). Global prescription stimulant market.
2. U.S. Food and Drug Administration. (2022). Approved amphetamine sulfate formulations.
3. IMS Health. (2022). ADHD medication market analysis.
4. European Medicines Agency. (2022). Schedule classifications for stimulant drugs.
5. WHO. (2022). Schedule II substances and control policies.